Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
11 pending office actions • 11 art units • 11 examiners • 0 of 11 (0%) have an AI response strategy ready • 16 patents granted in the last 365 days
Children's National Medical Center is managing 10 pending office actions in the Biotechnology & Pharmaceuticals technology area. The prosecution is distributed, with 10 distinct examiners each handling one of the 10 pending office actions. This distribution is also reflected in the 10 distinct art units involved, indicating a highly diverse set of technical applications. Each of the 10 pending office actions is being reviewed by a different examiner in a different art unit, requiring a highly individualized approach to each case.
FRITH, SEAN A is listed as the busiest examiner, though they only have 1 pending office action. This is consistent with the overall distribution where 10 distinct examiners are each responsible for a single case. The involvement of 10 distinct art units for only 10 pending office actions suggests that the center's research spans a wide variety of specialized biotechnological fields. This high level of technical and examiner diversity means the center must manage 10 separate examiner relationships across 10 different technical groups at the USPTO.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (9%) |
| §101 + other | 3 (27%) |
| §103 only | 3 (27%) |
| §102 only | 1 (9%) |
| Multi-statute (no §101) | 3 (27%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FRITH, SEAN A | 1 | 62.5% | +26.7% |
| DIETRICH, JOSEPH M | 1 | 80.8% | +8.6% |
| PARK, PATRICIA JOO YOUNG | 1 | 57.8% | +14.7% |
| BOSQUES, EDELMIRA | 1 | 63.0% | +20.6% |
| ROONEY, NORA MAUREEN | 1 | 60.3% | +23.6% |
| GOLOVAN, MARK | 1 | 100.0% | +0.0% |
| HANEY, AMANDA MARIE | 1 | 36.4% | +44.9% |
| ALABI, OYELEYE A | 1 | 84.0% | +25.2% |
| VIVLEMORE, TRACY ANN | 1 | 73.0% | +6.6% |
| MIDDLETON, DANAYA L | 1 | 48.5% | +49.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19108200 | RHEUMATIC HEART DISEASE DETECTION FROM ECHOCARDIOGRAMS | FRITH, SEAN A | 16d overdue |
| 18686890 | DEVELOPMENT OF A BEAT-TO-BEAT FETAL ELECTROCARDIOGRAM | DIETRICH, JOSEPH M | — |
| 18561080 | BURN INJURY MANAGEMENT USING A CALCULATION OF TOTAL BODY SURFACE AREA BURNED | PARK, PATRICIA JOO YOUNG | — |
| 18560257 | RETRACTABLE LOW-PROFILE PEDIATRIC GASTROSTOMY TUBE AND USES THEREOF | BOSQUES, EDELMIRA | — |
| 18259529 | CONNECTION PROTECTOR, SECUREMENT SYSTEM HAVING THE CONNECTION PROTECTOR AND USES THEREOF | GOLOVAN, MARK | — |
| 18251654 | CIRCULATING miRNA AND PROTEIN BIOMARKERS FOR FACIOSCAPULOHUMERAL DYSTROPHY | HANEY, AMANDA MARIE | — |
| 18301056 | REVERSE-PHASE HIGH PRESSURE LIQUID CHROMATOGRAPHY METHODS FOR MEASURING AMINO ACIDS, AMMONIUM, AND GLUTATHIONE CONCENTRATIONS IN BIOLOGICAL SAMPLES | ALABI, OYELEYE A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19108200 | RHEUMATIC HEART DISEASE DETECTION FROM ECHOCARDIOGRAMS | FRITH, SEAN A | 16d overdue |
| 17425130 | WHOLE CELL TUMOR VACCINES AND METHODS OF USE THEROF | MIDDLETON, DANAYA L | 28d |
| 18561080 | BURN INJURY MANAGEMENT USING A CALCULATION OF TOTAL BODY SURFACE AREA BURNED | PARK, PATRICIA JOO YOUNG | — |
| 18560257 | RETRACTABLE LOW-PROFILE PEDIATRIC GASTROSTOMY TUBE AND USES THEREOF | BOSQUES, EDELMIRA | — |
| 18219930 | NANOPARTICLE-MEDIATED IMMUNE CELL MANUFACTURE AND USE THEREOF | ROONEY, NORA MAUREEN | — |
| 18251654 | CIRCULATING miRNA AND PROTEIN BIOMARKERS FOR FACIOSCAPULOHUMERAL DYSTROPHY | HANEY, AMANDA MARIE | — |
| 18301056 | REVERSE-PHASE HIGH PRESSURE LIQUID CHROMATOGRAPHY METHODS FOR MEASURING AMINO ACIDS, AMMONIUM, AND GLUTATHIONE CONCENTRATIONS IN BIOLOGICAL SAMPLES | ALABI, OYELEYE A | — |
| Art Unit | Apps |
|---|---|
| 3798 | 1 |
| 3796 | 1 |
| 3792 | 1 |
| 3772 | 1 |
| 1641 | 1 |
| 3783 | 1 |
| 1682 | 1 |
| 1758 | 1 |
| 1638 | 1 |
| 1674 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19108200 | RHEUMATIC HEART DISEASE DETECTION FROM ECHOCARDIOGRAMS | FRITH, SEAN A | 3798 | §101 | Non-Final OA | 16d overdue | Pending | Mar 03, 2025 |
| 18686890 | DEVELOPMENT OF A BEAT-TO-BEAT FETAL ELECTROCARDIOGRAM | DIETRICH, JOSEPH M | 3796 | §102§103 | Final Rejection | — | Pending | Feb 27, 2024 |
| 18561080 | BURN INJURY MANAGEMENT USING A CALCULATION OF TOTAL BODY SURFACE AREA BURNED | PARK, PATRICIA JOO YOUNG | 3792 | §101§103 | Final Rejection | — | Pending | Nov 15, 2023 |
| 18560257 | RETRACTABLE LOW-PROFILE PEDIATRIC GASTROSTOMY TUBE AND USES THEREOF | BOSQUES, EDELMIRA | 3772 | §102§103 | Final Rejection | — | Pending | Nov 10, 2023 |
| 18219930 | NANOPARTICLE-MEDIATED IMMUNE CELL MANUFACTURE AND USE THEREOF | ROONEY, NORA MAUREEN | 1641 | §102 | Non-Final OA | — | Pending | Jul 10, 2023 |
| 18259529 | CONNECTION PROTECTOR, SECUREMENT SYSTEM HAVING THE CONNECTION PROTECTOR AND USES THEREOF | GOLOVAN, MARK | 3783 | §102§103§112 | Non-Final OA | — | Pending | Jun 27, 2023 |
| 18251654 | CIRCULATING miRNA AND PROTEIN BIOMARKERS FOR FACIOSCAPULOHUMERAL DYSTROPHY | HANEY, AMANDA MARIE | 1682 | §101§112 | Non-Final OA | — | Pending | May 03, 2023 |
| 18301056 | REVERSE-PHASE HIGH PRESSURE LIQUID CHROMATOGRAPHY METHODS FOR MEASURING AMINO ACIDS, AMMONIUM, AND GLUTATHIONE CONCENTRATIONS IN BIOLOGICAL SAMPLES | ALABI, OYELEYE A | 1758 | §101§102§103§112 | Non-Final OA | — | Pending | Apr 14, 2023 |
| 18008422 | USE OF RECOMBINANT HUMAN ACID SPHINGOMYELINASE TO IMPROVE SKELETAL MYOFIBER REPAIR | VIVLEMORE, TRACY ANN | 1638 | §103 | Final Rejection | 28d | Pending | Dec 05, 2022 |
| 17425130 | WHOLE CELL TUMOR VACCINES AND METHODS OF USE THEROF | MIDDLETON, DANAYA L | 1674 | §103 | Final Rejection | 28d | Pending | Jul 22, 2021 |
| 17421337 | EX VIVO ACTIVATED T-LYMPHOCYTIC COMPOSITIONS AND METHODS OF USING THE SAME | O'BRIEN, LEA S | 1646 | §103Other | Non-Final OA | 26d | Pending | Jul 07, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial